6.00
0.00 (0.00%)
| Previous Close | 6.00 |
| Open | 6.02 |
| Volume | 406,216 |
| Avg. Volume (3M) | 1,691,780 |
| Market Cap | 306,940,192 |
| Price / Sales | 37.76 |
| Price / Book | 7.23 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Diluted EPS (TTM) | -0.630 |
| Total Debt/Equity (MRQ) | 57.92% |
| Current Ratio (MRQ) | 4.90 |
| Operating Cash Flow (TTM) | -59.88 M |
| Levered Free Cash Flow (TTM) | -39.71 M |
| Return on Assets (TTM) | -49.95% |
| Return on Equity (TTM) | -271.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Abeona Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.14% |
| % Held by Institutions | 63.36% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rosalind Advisors, Inc. | 31 Mar 2025 | 1,805,817 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (HC Wainwright & Co., 233.33%) | Buy |
| 20.00 (Stifel, 233.33%) | Buy | |
| Median | 20.00 (233.33%) | |
| Low | 19.00 (Oppenheimer, 216.67%) | Buy |
| Average | 19.67 (227.83%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 6.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 02 Jun 2025 | 19.00 (216.67%) | Buy | 6.28 |
| Stifel | 16 May 2025 | 20.00 (233.33%) | Buy | 6.10 |
| HC Wainwright & Co. | 30 Apr 2025 | 20.00 (233.33%) | Buy | 6.56 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALVINO MARK | - | 5.83 | -13,093 | -76,332 |
| CHARLES FAITH L. | - | 5.83 | -10,738 | -62,603 |
| O'MALLEY BRENDAN M. | - | 5.83 | -17,428 | -101,605 |
| SESHADRI VISHWAS | - | 5.83 | -69,420 | -404,719 |
| SILVERSTEIN CHRISTINE BERNI | - | 5.83 | -13,093 | -76,332 |
| VAZZANO JOSEPH WALTER | - | 5.83 | -25,411 | -148,146 |
| WUCHTERL DONALD A. | - | 5.84 | -5,176 | -30,228 |
| Aggregate Net Quantity | -154,359 | |||
| Aggregate Net Value ($) | -899,965 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.83 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHARLES FAITH L. | Director | 09 Jul 2025 | Sell (-) | 10,738 | 5.83 | 62,603 |
| ALVINO MARK | Director | 09 Jul 2025 | Sell (-) | 13,093 | 5.83 | 76,332 |
| O'MALLEY BRENDAN M. | Officer | 09 Jul 2025 | Sell (-) | 17,428 | 5.83 | 101,605 |
| VAZZANO JOSEPH WALTER | Officer | 09 Jul 2025 | Sell (-) | 25,411 | 5.83 | 148,146 |
| SESHADRI VISHWAS | Officer | 09 Jul 2025 | Sell (-) | 69,420 | 5.83 | 404,719 |
| SILVERSTEIN CHRISTINE BERNI | Director | 09 Jul 2025 | Sell (-) | 13,093 | 5.83 | 76,332 |
| WUCHTERL DONALD A. | Director | 08 Jul 2025 | Automatic sell (-) | 5,176 | 5.84 | 30,228 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |